# Junta clínica — PT-pseudo_d49b896a09e6 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_d49b896a09e6",
  "pid": "PT-pseudo_d49b896a09e6",
  "task": 1,
  "psa": 6.7,
  "age": 67,
  "months": 1,
  "pirads": "4",
  "psad": 0.2,
  "psav": 1.78,
  "psap": 4.4,
  "vol": 36.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.7934635,
  "medhx": "Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30)",
  "meds": "rosuvastatin, aspirin 80 mg, atorvastatin",
  "notes": "PSA 6.7 ng/mL. PI-RADS 4. PSAD 0.20. Prostate volume 36 mL. csPCa 0.79.",
  "pmhx": [
    "Hypercholesterolaemia",
    "Coronary artery disease",
    "Obesity (BMI >30)"
  ],
  "allergies": [],
  "vitals": {
    "weight": "93 kg",
    "height": "178 cm",
    "bmi": "29.4",
    "bp": "146/77 mmHg",
    "hr": "77 bpm",
    "smoking": "Current smoker (17 pack-yr)",
    "last_dental": "3 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "31 Jan 2025",
  "enc_ref": "Dr. P. van Dijk (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "An upward PSA trend alongside a previously positive biopsy necessitates urological review."
    },
    {
      "s": "History",
      "t": "A widowed retired warehouse worker currently residing with his partner presents for surveillance after a positive biopsy yielded a Gleason 6 diagnosis. His medical background includes coronary artery disease, hypercholesterolaemia, and obesity (BMI >30). Daily medication consists of rosuvastatin, atorvastatin, and aspirin 80 mg. He maintains a 17 pack-year smoking history and consumes approximately 19 units of alcohol each week. Despite a consistent running routine covering five kilometres three times weekly, he reports moderate lower urinary tract symptoms scoring 13 on the IPSS scale, absent of significant nocturia or urgency. Cardiology reviewed him in November, confirming stable angina without recent procedures. An unrelated cataract evaluation occurred last month, and he mentions occasional mild fatigue he attributes to seasonal shifts rather than systemic disease. Distance to the hospital exceeds ninety minutes, leading him to prefer telephone consultations when clinically suitable."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth and symmetric; mobility: unremarkable; asymmetry: none. The digital rectal examination confirms a normal prostate without palpable irregularities. General inspection shows a well-nourished individual with a blood pressure reading of 146/77 mmHg and a regular pulse of 77 beats per minute. Palpation of the abdomen reveals a soft, non-tender abdomen free of masses or organomegaly."
    }
  ],
  "occupation": "retired warehouse worker",
  "marital": "Widowed",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Ophthalmology — cataract review"
  ],
  "alcohol": "19 units / week",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 13/35 (moderate LUTS)",
  "admin": "Lives >90 min from clinic; phone follow-up preferred where clinically safe.",
  "mri_hospital": "UMCG (Groningen)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d49b896a09e6
Task: 1

Encounter: Urology - outpatient on 31 Jan 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 6.7 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.2 ng/mL²
  - PSA velocity: 1.78 ng/mL/yr
  - Prior PSA: 4.4 ng/mL
  - Prostate volume: 36.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7934635 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30)
  - Problem list / PMHx: Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30)
  - Current medication: rosuvastatin, aspirin 80 mg, atorvastatin
  - Allergies: NKA
  - Additional notes: PSA 6.7 ng/mL. PI-RADS 4. PSAD 0.20. Prostate volume 36 mL. csPCa 0.79.

Vitals: weight 93 kg, height 178 cm, BMI 29.4, BP 146/77 mmHg, HR 77 bpm. Smoking: Current smoker (17 pack-yr).

Chief complaint: An upward PSA trend alongside a previously positive biopsy necessitates urological review.

History: A widowed retired warehouse worker currently residing with his partner presents for surveillance after a positive biopsy yielded a Gleason 6 diagnosis. His medical background includes coronary artery disease, hypercholesterolaemia, and obesity (BMI >30). Daily medication consists of rosuvastatin, atorvastatin, and aspirin 80 mg. He maintains a 17 pack-year smoking history and consumes approximately 19 units of alcohol each week. Despite a consistent running routine covering five kilometres three times weekly, he reports moderate lower urinary tract symptoms scoring 13 on the IPSS scale, absent of significant nocturia or urgency. Cardiology reviewed him in November, confirming stable angina without recent procedures. An unrelated cataract evaluation occurred last month, and he mentions occasional mild fatigue he attributes to seasonal shifts rather than systemic disease. Distance to the hospital exceeds ninety minutes, leading him to prefer telephone consultations when clinically suitable.

Physical examination: DRE — texture: smooth and symmetric; mobility: unremarkable; asymmetry: none. The digital rectal examination confirms a normal prostate without palpable irregularities. General inspection shows a well-nourished individual with a blood pressure reading of 146/77 mmHg and a regular pulse of 77 beats per minute. Palpation of the abdomen reveals a soft, non-tender abdomen free of masses or organomegaly.

Patient info: retired warehouse worker; Widowed; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 19 units / week; exercise Running 3x/week, 5 km; IPSS score: 13/35 (moderate LUTS).

Recent other appointments: Ophthalmology — cataract review.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: BIOPSY   p(biopsy) = 0.76
  uncertainty  +/- 0.14 (95% CI 0.49-1.00); among patients it cannot tell apart the outcome was 0.79 of 1.00 mixed
  confidence   MODERATE — in this tier it was right 80% of the time over 20 labelled cases

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. I have no answer for him, and that is the finding.

The criterion here is that the visible panel does not determine this decision: the man already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. Measured on the 49 labelled cases in this
situation: no structured variable separates the two answers — PSA is rising in all 49 — the
split is 26 defer / 23 biopsy, and every rule fitted on one half failed on the other.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle
this man and the retrieved documents have to.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a repeat biopsy is mandated if the MRI shows a lesion that mandates it to confirm histological progression. It also states that a stable MRI (PRECISE 1-3) with a low PSA-D (< 0.15) may allow for omission of a repeat biopsy.

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of biopsy is not sufficiently informed by the guideline because it fails to account for the critical role of the mpMRI prose. The guideline makes a decisive distinction based on the MRI findings, which the classifier's limited variables could not read. Furthermore, the guideline sets a threshold for PSA density (< 0.15) that the classifier's variables might not have adequately weighted to determine the decision.

WHAT WE STILL NEED
The mpMRI prose - the report does not compare against an earlier study, so the guideline does not support re-sampling.
The prior biopsy status - the panel indicates a prior positive biopsy, which is a key factor in determining the management pathway.
The previous notes - the notes mention an upward PSA trend alongside a previously positive biopsy necessitates urological review.
The laboratory results - the PSA value of 6.7 ng/mL is a known value, but the guideline requires context regarding PSA density to assess stability.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on the specific findings within the mpMRI report and the context provided in the previous notes to determine if a repeat biopsy is indicated.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine the mpMRI prose, including lesion characteristics and comparison to prior studies.
  previous_notes (get_previous_notes) -> Establish the management context regarding the upward PSA trend and prior biopsy result.
  psa_trend (get_psa_trend) -> What shape does the serial PSA have — rising, flat, falling or oscillating — and over what period?

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What does the mpMRI report state regarding the lesion size, zone, and extraprostatic extension, and how does it compare against an earlier study?
  Q2. What is the context provided in the previous notes regarding the upward PSA trend in light of the prior positive biopsy?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel. psa_trend was added to the plan: the reading urologist opened it in 87% of the labelled cases, and it carries a fact this decision turns on.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI report states the lesion is a PI-RADS 4 abnormality measuring approximately 12 x 8 mm in the left peripheral zone at the mid-gland level, and it shows prompt, localized contrast uptake with no seminal vesicle invasion or extraprostatic extension. It does not explicitly compare against an earlier study.

previous_notes
The previous notes establish the context that the PSA climbed to 4.4 ng/mL, and given the upward trajectory and a prior positive biopsy, he was referred to urology for further assessment.

psa_trend
The serial PSA has shown a rising trend from 3.0 ng/mL in Oct 2023 to 6.7 ng/mL in Jan 2025.

WHAT I DID NOT OPEN
laboratory_results
I did not open the laboratory results because the moderator did not ask for them in the plan, and the key information regarding free-PSA fraction, infection, or prostatitis was not explicitly requested by the moderator's questions.

WHAT THIS SUPPORTS
FOR sampling this patient now
The mpMRI report identifies a PI-RADS 4 lesion, which is a key factor in the EAU guideline consideration.
The previous notes confirm the clinical context of an upward PSA trend following a prior positive biopsy.

AGAINST sampling this patient now
The cohort criterion indicates that the prior positive biopsy means the panel cannot settle the decision, as the split is 26 defer / 23 biopsy.

WHERE THIS LEANS
The findings suggest that the mpMRI findings and the context of the rising PSA trend are critical for the decision, leaning towards further investigation.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar has answered Q1 by stating the lesion is a PI-RADS 4 abnormality measuring 12 x 8 mm in the left peripheral zone with no seminal vesicle invasion or extraprostatic extension, but it did not address the comparison to an earlier study.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the classifier's suggestion of biopsy because the registrar noted the PI-RADS 4 lesion and the context of the rising PSA trend, which the EAU specialist noted as critical.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the mpMRI report state regarding the lesion size, zone, and extraprostatic extension, and how does it compare against an earlier study? This is partially answered by the registrar, who described the size and location but noted the report did not explicitly compare against an earlier study.
Q2. What is the context provided in the previous notes regarding the upward PSA trend in light of the prior positive biopsy? This is answered by the registrar, who confirmed the PSA climbed to 4.4 ng/mL and noted the referral context.

WHAT CARRIES WEIGHT, AND WHY
The variables relevant to the EAU guideline are the mpMRI findings because the guideline mandates repeat biopsy based on lesion characteristics, and the psa_trend because the guideline requires context on PSA stability. The prior biopsy status is a factor the cohort criterion suggests prevents a clear decision. The guideline does not explicitly support the panel's leaning towards deferral.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a repeat biopsy to confirm histological progression, as the mpMRI findings and the rising PSA trend provide the necessary context for this decision according to the guideline's framework.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

A repeat biopsy is recommended because the mpMRI identified a PI-RADS 4 lesion, and the serial PSA trend showed a rise from 3.0 ng/mL to 6.7 ng/mL. This finding aligns with the EXPERT-CLASSIFIER's suggestion, which was supported by the Registrar's retrieval of the rising PSA trend and the PI-RADS 4 finding, which together provide the necessary context for further investigation.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=important, cspca=noted, pirads=important, comorbidity=important
Documents this conference opened: radiology_report, previous_notes, psa_trend
